PointState Capital’s Revance Therapeutics, Inc. RVNC Stock Holding History

PointState Capital’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-438,200	Closed	-$11.6M	–	177
2017 Q2	$11.6M	Buy	438,200 +161,700	+58%	+$3.61M	0.13%	83
2017 Q1	$5.75M	Buy	276,500 +101,500	+58%	+$2.08M	0.06%	110
2016 Q4	$3.62M	Sell	175,000 -150,000	-46%	-$2.51M	0.05%	101
2016 Q3	$5.27M	Buy	325,000 +75,000	+30%	+$1.09M	0.05%	103
2016 Q2	$3.4M	Buy	+250,000	New	+$4.42M	0.07%	76

Other funds holding RVNC

EWM

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

PointState Capital's RVNC Position: Q3 2017 in Review

PointState Capital sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2017, closing a stake of 438,200 shares — an estimated $11.6M sold.

PointState Capital first reported a position in RVNC in Q2 2016 and held it in 5 quarters. The position peaked at $11.6M in Q2 2017. 85 funds tracked by Wall St. Rank hold RVNC as of Q3 2017.

PointState Capital reported no remaining Revance Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
PointState Capital sold 438,200 Revance Therapeutics, Inc. shares in Q3 2017, an estimated $11.6M.
PointState Capital first reported a position in Revance Therapeutics, Inc. in Q2 2016 and held it in 5 quarters.
PointState Capital's Revance Therapeutics, Inc. position peaked at $11.6M in Q2 2017.
85 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2017.

Based on PointState Capital's 13F filing for Q3 2017, filed 14 Nov 2017.